LOS ANGELES, July 21, 2025 /PRNewswire/ — Reolink, an innovative leader in intelligent visual technology for the home, proudly announces the launch of its latest smart security solution: Elite Floodlight WiFi, a 4K 8MP dual-lens floodlight camera with AI-powered monitoring. As the world’s first floodlight camera to feature local AI Video Search^Beta, it introduces an intuitive way for users to instantly locate the exact video clips they need using simple, descriptive phrases. Combined with an ultra-wide field of view and advanced lighting, this camera delivers smarter, faster, and more reliable protection—all without subscription fees.

Reolink Elite Floodlight WiFi is now available for presale in the North American market through Reolink.com, with a retail price starting from $219.99.

A Camera Designed Around Pain Points

Many home security cameras struggle to keep up with real-world needs—critical moments get buried in hours of footage, key events slip past in blind spots, and suspicious activity often draws no attention when immediate response is needed most—especially at night when poor lighting makes it harder to see and respond. These common limitations can leave users feeling unprotected at the very moments they rely on their cameras most.

As part of Reolink’s commitment to user-centric innovation, Elite Floodlight WiFi brings a powerful combination of hardware and intelligence to solve these issues. With intelligent features like AI Video Search^Beta, an expansive 180° field of view, and adaptive lighting up to 3000 lumens, Elite Floodlight WiFi is purpose-built to help users see more, find faster, and protect better.

Intelligent Search Starts Here: Local AI Video Search^Beta

Elite Floodlight WiFi introduces industry-leading Local AI Video Search^Beta—a smarter, faster way to locate exactly what you’re looking for. Instead of scrubbing through hours of footage, users can type phrases like “man in a white hoodie” or “black pickup truck” to instantly find matching events. The system supports search categories including people, vehicles, animals, and even packages.

This advanced search capability, powered by ReoNeura^TM—Reolink’s smart AI system—runs entirely on the device, with no cloud connection or subscription required. It’s a private, intuitive way to take control of your footage and respond faster when it matters most.

180° Field of View, Blindspot-free in 4K

Reolink Elite Floodlight WiFi features advanced dual-image stitching technology to deliver a seamless 180° panoramic view in stunning 4K UHD. Designed to cover wide, open areas with a single device, it captures every corner with clarity—making it ideal for driveways, front yards, or commercial spaces where full-scene visibility is critical.

Powerful Floodlights for Night Time Protection

Elite Floodlight WiFi’s built-in floodlights provide up to 3000 lumens of brightness, giving users the flexibility to light up outdoor spaces as needed. Choose a warm 3000K glow for ambiance or a crisp 6000K cool light for enhanced visibility and color accuracy.

Its smart adaptive lighting modes automatically adjust brightness and color temperature based on time of day or detected activity. Users can choose from three smart lighting modes: Tailor Your Lighting for manual brightness and timing control, Dusk-to-Dawn for ambient light-based automation, and Motion-Triggered to activate lights, along with the siren (up to 105dB), if enabled, when people, vehicles, or animals are detected.

Effective Deterrence with Smarter Detection

This camera also features AI-powered motion detection that accurately distinguishes between people, vehicles, and animals—reducing false alarms and improving response precision. When activity is detected, users receive real-time app alerts and can trigger customizable warnings, such as sirens or voice messages.

Beyond basic detection, users can create customizable alert rules with smart AI: draw a virtual fence to monitor specific directions, define zones to trigger alarms when movement occurs, or set linger alerts for when people or vehicles remain too long in sensitive areas.

This launch reflects Reolink’s ongoing commitment to user-centric innovation—delivering advanced, reliable security designed for how people actually live. By combining powerful features with intuitive design and private, subscription-free operation, Reolink continues to redefine smart home protection for real-world needs.

To learn more about Reolink Elite Floodlight WiFi, please visit Reolink.com.

About Reolink

Reolink offers smart security solutions for homes and businesses, aiming for a seamless security experience with its wide range of products. Serving millions globally, it provides video surveillance and protection, standing out for its commitment to security technology innovation. Learn more about Reolink’s offerings at Reolink.com.

PARSIPPANY, N.J., July 21, 2025 /PRNewswire/ — Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has announced it successfully passed the U.S. Food and Drug Administration (FDA)’s on-site GMP audit with a “No Action Indicated” (NAI) result. This is the best possible result, confirming complete compliance with no objectionable conditions (“zero-deficiency”).

The FDA’s issuance of a Current Good Manufacturing Practice (CGMP) compliance notification and Establishment Inspection Report (EIR) formally recognizes Bloomage’s pharmaceutical quality system as fully aligned with international regulatory expectations. The recognition not only affirms Bloomage’s commitment to excellence in quality management but also significantly strengthens its position in global markets, providing international partners and customers with added confidence.

FDA Certification: The Global Gold Standard for Pharmaceutical Quality

The FDA is widely recognized as one of the most rigorous drug regulatory agencies in the world. Its authority stems from its comprehensive and strict oversight of the entire drug lifecycle, from research and development to manufacturing and distribution, encompassing areas such as data integrity, quality assurance, and risk management systems.

The five-day audit of Bloomage was conducted in accordance with ICH Q7 guidelines for active pharmaceutical ingredients (APIs) and covered six core systems: Quality, Facilities and Equipment, Materials, Production, Laboratory Control, and Packaging & Labeling. Additionally, the inspection included in-depth verification of computerized systems and electronic records.

Achieving a “zero-deficiency” result under this level of scrutiny demonstrates Bloomage’s precise operational control and its unwavering commitment to high-quality standards.

Notably, this is not the company’s first “zero-deficiency” outcome from a national regulator in a major global market. In February 2025, Bloomage also passed an on-site GMP inspection by the Ministry of Food and Drug Safety (MFDS) of South Korea. That three-day inspection, conducted by two official auditors, concluded with the best possible result, confirming full compliance with no objectionable conditions (“zero-deficiency”).

To date, Bloomage’s sodium hyaluronate API products have successfully passed five FDA inspections, one inspection by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and two MFDS inspections in Korea. These achievements not only demonstrate the company’s regulatory strengths, but also provide a solid compliance foundation for collaborations with partners around the world.

Sustained Quality, Global Trust: How Bloomage Scales with Precision and Compliance

Bloomage has become a trusted global supplier by delivering world-class product quality and a consistent track record of regulatory approvals. Its sodium hyaluronate APIs have obtained 34 registrations and filings across the European Union, United States, Japan, Korea, Canada, Russia, India, etc. This includes 11 Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) and 10 Drug Master File (DMF) filing with the U.S. FDA — making Bloomage one of the most comprehensively registered sodium hyaluronate suppliers in the world.

Bloomage has spent more than two decades providing high-quality, cutting-edge bioactive raw materials and tailored solutions to many of the world’s leading companies in sectors ranging from beauty & care and pharma & aesthetics to nutrition & health.

The company now operates a global marketing and supply network covering over 70 countries and regions, with subsidiaries established in the United States, France, Japan, Korea, and Singapore.

Bloomage continues to explore the potential of emerging markets by strengthening R&D and responding flexibly to evolving global demand. Its ability to allocate resources efficiently and tailor services to specific regional needs reflects its agility in navigating diverse market landscapes.

Certifications as a Strategic Foundation

Sustainable brand strength is not built on marketing alone. An integrated infrastructure of quality systems, reliable supply chains, and the ability to adapt to increasingly complex global regulatory environments is required.

For Bloomage, long-term investment in R&D and international certifications forms the foundation of its product excellence and market competitiveness. These efforts underpin the company’s ability to deliver superior products and maintain a trustworthy brand image.

Rather than viewing compliance as a cost, Bloomage sees it as a strategic moat. The company has built a full-chain system that integrates technical standards, quality control, and global regulatory alignment. This enables it to lead with substance, not slogans, and win trust in even the most competitive and tightly regulated markets.

About Bloomage

Since its founding in 2000, Bloomage has grown into a leading international company specializing in the research, development, production, and sale of hyaluronic acid and other bioactive substances for the pharmaceutical, cosmetic and functional foods industries. Bloomage’s commitment to quality, innovation, and sustainable innovations have established the company as a trusted name for some of the world’s most renowned brands. It now serves more than 4,000 customers in over 70 countries.
Learn more at Bloomage.com 

Media Contact
Cecilia Qian
cecilia@impact5r.com 

PHILADELPHIA, July 21, 2025 /PRNewswire/ — Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. 

Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster.

Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: “On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies.”

Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented: “I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company’s strong foundations and drive its next phase of growth.”

About Minaris Advanced Therapies:

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.

Minaris Advanced Therapies is a portfolio company of Altaris.

www.minaris.com

About Altaris:

Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com

Media Contact:

Tihesha Aaron

corp.communications@minaris.com

Dr. Orla Cloak, Recently Appointed Chief Executive Officer, Minaris Advanced Therapies

NEW YORK, July 21, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on July 21st

• Over the weekend, the White House reiterated its position on tariffs. U.S. Commerce Secretary Howard Lutnick said August first is the “hard deadline” for countries to begin payment.
• Corporate earnings season is ramping up with several companies including Alphabet and Tesla set to report this week. 59 S&P 500 companies have reported this season with 86% beating expectations.
• The FIFA World Cup 2026 New York/New Jersey host committee will ring the opening bell. Tammy Murphy, board chair, will do the honors as the world sits one year out from the final match in 2026.

Opening Bell
FIFA World Cup 26 NYNJ Host Committee will mark one year to the final match of the World Cup

Closing Bell
Western Union (NYSE: WU) celebrates its upcoming 175^th anniversary helping people around the world save, spend, and transfer money

Click here to download the NYSE TV App